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ABSTRACT:  
Introduction: In a previous phase, 12 draft-definitions for clinically important worsening 
in axial spondyloarthritis (axSpA) were selected, of which 3 were based on absolute 
changes in ASDAS-CRP (ASDAS). The objective here was to select the best cut-off for the 
ASDAS for clinically important worsening in axSpA for use in clinical trials and 
observational studies. 
Methods: An international longitudinal prospective study evaluating stable axSpA 
patients was conducted. Data necessary to calculate ASDAS were collected at 2 
consecutive visits (spaced 7 days to 6 months). Sensitivity and specificity of the 3 cut-offs 
for change in ASDAS were tested against the patient’s subjective assessment of worsening 
as the external standard (i.e., the patient reporting that he had worsened and felt a need 
for treatment intensification). Final selection was made by a consensus and voting 
procedure among ASAS members. 
Results: In total, 1169 axSpA patients were analysed: 64.8% were males and had a mean 
age of 41.7 (SD 12.4) years. At the second visit, 127 (10.9%) patients judged their situation 
as worsened.  
Sensitivity and specificity for an increase of at least 0.6, 0.9 and 1.1 ASDAS points to detect 
patient-reported worsening were 0.55 (Se) and 0.91 (Sp), 0.38 (Se) and 0.96 (Sp), and 0.33 
(Se) and 0.98 (Sp)  respectively. The ASAS consensus was to define clinically important 
worsening as an increase in ASDAS of at least 0.9 points. 
Conclusion: This data-driven ASAS consensus process resulted in an ASDAS-based cut-off 
value defining clinically important worsening in axSpA for use in trials. 
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The course of axial spondyloarthritis (axSpA) is characterized by periods of flares (clinical 
worsening) and remission. Current definitions for clinical disease worsening in axSpA are 
very heterogeneous across clinical trials. This is a particular problem in discontinuation 
trials, which aim to discontinue the treatment in patients in remission and only resume 
the treatment in case of disease worsening. The absence of a consensual definition for 
clinically important worsening of disease activity in axSpA jeopardises the interpretation 
of - and comparison across - trials.  
The Assessment of SpondyloArthritis international Society (ASAS) is a world-wide 
independent consortium of experts in spondyloarthritis (SpA), which has developed and 
validated most of the criteria and outcome measures currently used in SpA clinical trials. 
This includes the Ankylosing Spondylitis Disease Activity Score (ASDAS) as a disease 
activity measure with validated cut-offs for various disease activity states and -
improvements.[1,2] ASAS has decided to define also a cut-off for clinically important 
worsening in axSpA. The first two steps of this process have been already reported [3]: 
first, a systematic literature review of definitions of ‘disease worsening’ in published 
randomized controlled trials in axSpA was performed, yielding 38 studies using some 
definition of ‘disease worsening’ and 27 different definitions, most frequently based on 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [4] or pain. Second, a vignette 
exercise was performed involving 121 ASAS experts and 140 scenarios of disease 
worsening: each scenario included a change in one of the outcomes (pain, BASDAI, BASDAI 
plus C-reactive protein (CRP) or ASDAS [1]). Each ASAS expert judged for each of 46 
randomly developed scenarios if the scenario was compatible with disease worsening 
(yes/no). Receiver-operating characteristic analyses were applied to derive optimal cut-
off values for pain (N=3), BASDAI (N=5) and ASDAS (N=4), leading to 12 preliminary 
definitions of ‘worsening’ in axSpA, based on widely used indices. These results were 
presented at the 2015 annual ASAS workshop. It was felt that, based on the currently 
available data, it was impossible to prioritize one of the 12 scenarios, and that arguments 
for a further reduction of the number of scenarios should come from data observed in 
clinical practice.  
Thus, we conducted a clinical observational study aiming to evaluate the psychometric 
properties of the 12 draft definitions of clinically important worsening in axial SpA. The 
results of the study were presented at the 2017 annual ASAS workshop and a consensus 
and voting procedure has resulted in a final choice.  
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METHODS 
Study design : An international (including 20 countries), longitudinal (2 visits: with an 
interval between 1 week – 6 months), observational study was conducted in 2016. The 
study was conducted in agreement with good clinical practice, approved by ethics 
committees (at the local level) and a written informed consent was obtained from all 
patients. Patients: axSpA patients with stable disease (no need for a treatment change) 
according to the rheumatologist. Data collected: Demographics and disease 
characteristics were collected at baseline, and data on disease activity (including CRP) 
were collected at both visits. Clinical worsening was defined at the follow-up visit by the 
patient answering the following question (« Think about all the ways your 
spondyloarthritis has affected you during the last 48 hours. Compared to the last visit how 
did you feel during the last 48 hours? Improved/No change/Worse”). When patients 
answered “worse” they were asked if they considered treatment intensification was 
necessary (yes/no). Patient’s perception of worsening was defined as the patient 
reporting that he/she had worsened and that he/she felt there was a need for treatment 
intensification. 
Analysis: 
Pain: question 2 of the BASDAI (back Pain) was used. Three pain-based cut-offs were 
proposed based on the previous exercise [3] (see Table 2).   
BASDAI: BASDAI was calculated as follows: (Fatigue + Back Pain+ Peripheral Pain + 
Entheseal Pain + ((Level of Morning Stiffness + Duration of Morning Stiffness)/2))/5 [4].  
Five BASDAI cut-offs were proposed [3] (Table 2).  
ASDAS: the ASDAS formula with CRP was used (i.e. ASDAS = 0.12 × Back Pain + 0.06 × 
Duration of Morning Stiffness + 0.11 × Patient Global + 0.07 × Peripheral Pain/Swelling + 
0.58×Ln(CRP+1)). When the CRP level was below the limit of detection or <2 mg/lL, the 
constant value of 2 mg/L was used to calculate the ASDAS score as recommended [2].   
Four ASDAS-based cut-offs were proposed based on the previous exercise, with only 3 
absolute changes:[3] an increase in ASDAS of at least 0.6; an increase in ASDAS of at least 
0.6 points and a final ASDAS ≥1.3; an increase in ASDAS of at least 0.9 points; and an 
increase in ASDAS of at least 1.1 points; 
Sensitivity (that is: the likelihood to be considered as ‘worse’ by the scenario among all 
patients considering themselves worse) and specificity (that is:  the likelihood to be 
considered as ‘not worse’ by the scenario, among all patients not considering themselves 
worse) were tested.  
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The results of this analysis were presented at the 2017 annual ASAS workshop together 
with the previous results from the 2015 consensus (based on the physician’s perspective), 
followed by a consensus and voting procedure by the ASAS members. 
 
RESULTS  
The flow chart of the study is summarized in Fig 1: among the 1639 patients included, 
1169 patients provided complete data. Patients were predominantly male (64.8%) and 
had a mean (SD) age of 41.7 (12.4) years. History of radiographic sacroiliitis, MRI sacroiliitis 
and HLAB27 positivity were reported in 944 (80.8%), 471 (40.6%) and 807 (69.0%) 
patients, respectively. Baseline means (SD) for BASDAI (0-10), ASDAS and CRP were 3.1 
(2.3),  2.3 (1.0)  8.4mg/L (14.5) respectively (Table 1).  
The mean interval between both visits was 91.2 (SD 51.0) days, and at follow-up visit, 
means (SD) for BASDAI, ASDAS and CRP were 2.9 (2.2), 2.1 (1.0) and 7.4 (11.8) mg/L.  
A total of 590 (50.5%), 388 (33.2%) and 191 (16.3%) patients considered their condition 
as improved, not changed and worsened, respectively. Among the 191 patients reporting 
a worsening, 127 (66.5%) found that their status required treatment intensification. Thus, 
127 (10.8%) patients fulfilled the external standard definition of clinical worsening 
according to the patient’s perception. Table 2 summarizes these performances, along with 
those from the physician case-vignette exercise in which the external standard was the 
physician’s perception[3]. The 3 cut-offs of ASDAS change (i.e. increase of 0.6, 0.9 and 1.1 
points) yielded a sensitivity of 0.55, 0.38 and 0.33, respectively, and a specificity of 0.91, 
0.96 and 0.98, respectively. 
In January 2017, the ASAS membership discussed the data at length. Almost all ASAS 
members were in favour of selecting a cut-off based on the data (67 votes in favor vs. 1 
against). All members were against defining a cut-off based on pain. No consensus was 
reached for a BASDAI-based definition due to limited performance of all cut-offs, and 50% 
of members voted against deciding a cut-off for BASDAI.  
Regarding ASDAS cut-offs, the majority chose the cut-off of at least 0.9 point increase as 
the definition for clinically important worsening (6 votes in favor of 0.6;  64 votes in favor 
of 0.9 and no votes in favor of 1.1 n=0 (6 abstained)).  Thus, an increase of at least 0.9 
points was retained as the ASAS-definition for clinically important worsening in axSpA, to 
be used in studies.  
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DISCUSSION 
This three-step data-driven ASAS consensus process has allowed proposing an ASDAS-
based cut-off value defining clinically important worsening in axSpA. The final definition 
is the result of a comprehensive process involving a systematic literature review, a case-
vignette exercise using the physician’s perspective as external standard[3], a real-life 
study on worsening with the patient’s perspective as external standard and a consensus 
and voting procedure among SpA experts.  
Several cut-offs have already been defined for ASDAS, but only for either improvement 
changes or status.[6] It is worth noting that the minimum clinically important 
improvement of ASDAS is defined as a decrease of at least 1.1 points, which is a greater 
change than the change required for the predicate of clinically important worsening. This 
seemingly paradoxical finding is not unusual:  in other disciplines MCID-thresholds for 
deterioration have often been reported to be lower than for improvement. [7,8] 
A potential limitation of this study was the discrepancy between patient’s and physician’s 
perception in terms of sensitivity: indeed, when tested against patient’s perception, cut-
offs yielded much lower sensitivity values as compared with physician’s perception. This 
is not surprising, as patients might report feeling worse already at much lower changes as 
compared to physicians, and such discrepancies have been grounded in the literature [9].  
Secondly, the 0.9 ASDAS point increase definition had only moderate sensitivity (0.38) 
against the patient’s perception, but excellent specificity against both patient’s and 
physician’s perception. This high level of specificity was considered more important than 
sensitivity since the definition will be used in the context of clinical trials. The definition 
for clinically important worsening will typically be used in a treatment-withdrawal trial: a 
SpA-patient will stop treatment if clinical remission has been achieved and will resume 
the treatment in case of ‘true worsening’. A high specificity reduces the number of “false-
positive worsenings” and the subsequent (unnecessary) retreatment.  
In summary, a definition for clinically important worsening in axSpA based on the ASDAS 
has been defined, validated and endorsed by ASAS. This definition should now be used  in 
clinical trials and follow-up studies. 
 
  
 9 
REFERENCES 
1  Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease 
activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 
2009;68:18–24. doi:10.1136/ard.2008.094870 
2  Machado P, Navarro-Compán V, Landewé R, et al. Calculating the ankylosing 
spondylitis disease activity score if the conventional c-reactive protein level is below the 
limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR 
cohort. Arthritis Rheumatol Hoboken NJ 2015;67:408–13. doi:10.1002/art.38921 
3  Gossec L, Portier A, Landewé R, et al. Preliminary definitions of ‘flare’ in axial 
spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Ann Rheum 
Dis 2016;75:991–6. doi:10.1136/annrheumdis-2015-208593 
4  Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease 
status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J 
Rheumatol 1994;21:2286–91. 
5  Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in 
patient reported outcomes in knee and hip osteoarthritis: the patient acceptable 
symptom state. Ann Rheum Dis 2005;64:34–7. doi:10.1136/ard.2004.023028 
6  Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score 
(ASDAS): defining cut-off values for disease activity states and improvement scores. Ann 
Rheum Dis 2011;70:47–53. doi:10.1136/ard.2010.138594 
7  Mannion AF, Porchet F, Kleinstück FS, et al. The quality of spine surgery from the 
patient’s perspective: part 2. Minimal clinically important difference for improvement 
and deterioration as measured with the Core Outcome Measures Index. Eur Spine J Off 
Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 2009;18 Suppl 
3:374–9. doi:10.1007/s00586-009-0931-y 
8  Horváth K, Aschermann Z, Kovács M, et al. Minimal clinically important 
differences for the experiences of daily living parts of movement disorder society-
sponsored unified Parkinson’s disease rating scale. Mov Disord Off J Mov Disord Soc 
2017;32:789–93. doi:10.1002/mds.26960 
9  Desthieux C, Molto A, Granger B, et al. Patient-physician discordance in global 
assessment in early spondyloarthritis and its change over time: the DESIR cohort. Ann 
Rheum Dis 2016;75:1661–6. doi:10.1136/annrheumdis-2015-208251 
 
 
 
 
 
 
  
 10
TABLES 
Table 1: Patients and disease characteristics (n=1169) 
 Total population 
N=1169 
Age (years) (n=1168)* 42.0 [32.0-50.0] 
Gender (Male) 758 (64.8%) 
HLA-B27 + (n=1137) 807 (69.0%) 
Disease duration (years) (n=1163) 10.0 [5.0-18.0] 
Radiographic sacroiliitis (n=1164) 944 (80.8%) 
MRI Sacroiliitis (n=1161) 
 Positive 
 Negative 
 Never performed 
 
471 (40.6%) 
102 (8.8%) 
588 (50.6%) 
Current NSAID intake (n=1168) 826 (70.7%) 
Current biologic treatment (n= 1167) 655 (56.0%) 
CRP (mg/L) 3.7 [2.0-9.2] 
BASDAI (0-10) 2.8 [1.1-4.8] 
ASDAS 2.1 [1.4-3.0] 
Footnote: * results are presented as median [Q1-Q3] or as number (%); 
Abbreviations : NSAID: non-steroidal anti-inflammatory drugs; CRP: C-reactive protein; BASDAI : Bath 
Ankylosing Spondylitis Disease activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score.  
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Table 2: Performances of the cut-offs defining clinically important worsening 
 
  
Prospective real-life 
study 
(N=1169 patients) 
against the external 
standard 
'patient-worsening’ 
(worsening: N=127) 
2015 case -vignette 
exercise1 
(N=1150 physician 
judgments) 
against the external 
standard 
‘physician-worsening’ 
(worsening: N=591) 
 
 
Cut-off Sensitivity Specificity Sensitivity Specificity 
Back Pain 
(0-10) 
Δ pain ≥ 2 AND final pain ≥ 4 0.42 0.91 0.99 0.30 
Δ pain ≥ 3 0.29 0.95 0.95 0.69 
If Back Pain value is ≥ 4, then Δ pain ≥ 2 
points, if else, Δ pain ≥ 3 points 0.43 0.91 0.97 0.56 
BASDAI 
(0-10) 
Δ BASDAI ≥ 2 points 0.31 0.96 0.99 0.40 
Δ BASDAI ≥ 2 points AND final BASDAI ≥ 4 0.24 0.98 0.99 0.32 
Δ BASDAI ≥ 3 points 0.17 0.99 0.92 0.70 
Δ BASDAI ≥ 3 points AND final BASDAI ≥ 4 0.16 0.99 0.94 0.63 
If BASDAI value is ≥ 4, then Δ BASDAI ≥ 2 
points, if else, Δ BASDAI ≥ 3 points 0.25 0.98 0.94 0.54 
 
ASDAS 
 
ΔASDAS ≥0.6 0.55 0.91 0.97 0.65 
ΔASDAS ≥0.9 0.38 0.96 0.85 0.87 
ΔASDAS ≥1.1 0.33 0.98 0.60 0.94 
Δ ASDAS ≥0.6 AND final ASDAS ≥1.3 0.55 0.91 0.97 0.59 
1: Gossec L, et al. Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an 
ASAS initiative. Ann Rheum Dis. 2016;75:991-6. 
Footnote: ASDAS: Ankylosing Spondylitis Disease Activity Score-CRP. BASDAI:  Bath  Ankylosing  Spondylitis Activity Index;  
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FIGURE LEGENDS 
Figure 1: Flow Chart of the Study. 
 
Footnote: BASDAI : Bath Ankylosing Spondylitis Disease Activity Index; CRP : C-reactive Protein; 
ASDAS: Ankylosing Spondylitis Disease Activity Score - CRP 
 
 
 
 
 
 
 
